ImmunoGen Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ImmunoGen stock.
View analyst ratings for ImmunoGen or view top-rated stocks.

Wall Street analysts have given ImmunoGen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ImmunoGen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for ImmunoGen.

ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Monday, May, 10th. The biotechnology company reported ($0.17) EPS for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.02. The biotechnology company earned $15.70 million during the quarter, compared to analysts' expectations of $17.52 million. ImmunoGen had a negative trailing twelve-month return on equity of 169.72% and a negative net margin of 36.62%. ImmunoGen's quarterly revenue was up 18.0% compared to the same quarter last year.
View ImmunoGen's earnings history.

ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMGN stock has increased by 98.2% and is now trading at $6.68.
View which stocks have been most impacted by COVID-19.

ImmunoGen issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $65 million-75 million, compared to the consensus revenue estimate of $70.02 million.

7 Wall Street analysts have issued 12-month price targets for ImmunoGen's stock. Their forecasts range from $6.00 to $14.00. On average, they expect ImmunoGen's stock price to reach $10.10 in the next year. This suggests a possible upside of 51.2% from the stock's current price.
View analysts' price targets for ImmunoGen or view top-rated stocks among Wall Street analysts.

16 employees have rated ImmunoGen CEO Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among ImmunoGen's employees.

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of IMGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.16%), Redmile Group LLC (4.85%), Orbimed Advisors LLC (4.57%), Clearbridge Investments LLC (3.06%), Ameriprise Financial Inc. (2.80%) and Morgan Stanley (2.10%). Company insiders that own ImmunoGen stock include Craig Barrows, David G Foster, Mark J Enyedy and Thomas Ryll.
View institutional ownership trends for ImmunoGen.

IMGN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Redmile Group LLC, Clearbridge Investments LLC, Morgan Stanley, Cubist Systematic Strategies LLC, Credit Suisse AG, Allianz Asset Management GmbH, and Panagora Asset Management Inc..
View insider buying and selling activity for ImmunoGen or view top insider-selling stocks.

IMGN stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Ameriprise Financial Inc., Compagnie Lombard Odier SCmA, BlackRock Inc., D. E. Shaw & Co. Inc., Federated Hermes Inc., Geode Capital Management LLC, and Citigroup Inc..
View insider buying and selling activity for ImmunoGen or or view top insider-buying stocks.

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMGN stock can currently be purchased for approximately $6.68.

ImmunoGen has a market capitalization of $1.34 billion and generates $132.30 million in revenue each year. The biotechnology company earns $-44,370,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.

ImmunoGen employs 79 workers across the globe.

The official website for ImmunoGen is www.immunogen.com.

ImmunoGen is headquartered at 830 WINTER ST, WALTHAM MA, 02451.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]